Jenzano J W, Courts N F, Timko D A, Lundblad R L
J Dent Res. 1986 Jan;65(1):67-70. doi: 10.1177/00220345860650011201.
Glandular kallikrein activity in whole saliva was determined in 16 patients with malignant tumors distant from the oral cavity and in an equal number of healthy control subjects of similar age and sex distribution. The level of glandular kallikrein was significantly greater in saliva obtained from the patients with solid tumours as determined with a tripeptide nitro-anilide substrate, D-Val-Leu-ArgpNA. A basis for the higher levels of glandular kallikrein in saliva obtained from the solid tumor patients has not been established, nor is it possible to establish a role for glandular kallikrein in the pathogenesis of malignant disease. The higher level of glandular kallikrein observed in whole saliva obtained from patients with solid tumors suggests the need for further investigation of the role of kallikrein in malignant disease and the usefulness of salivary measurements of this enzyme as a reflection of systemic changes.
在16例患有远离口腔的恶性肿瘤患者以及相同数量、年龄和性别分布相似的健康对照者中,测定了全唾液中的腺激肽释放酶活性。用三肽硝基苯胺底物D-缬氨酸-亮氨酸-精氨酸对硝基苯胺(D-Val-Leu-ArgpNA)测定发现,实体瘤患者唾液中的腺激肽释放酶水平显著更高。实体瘤患者唾液中腺激肽释放酶水平较高的原因尚未明确,也无法确定腺激肽释放酶在恶性疾病发病机制中的作用。在实体瘤患者的全唾液中观察到较高水平的腺激肽释放酶,这表明需要进一步研究激肽释放酶在恶性疾病中的作用,以及唾液中该酶的测量作为全身变化反映的有用性。